Remdesivir and Dexamethasone for the Treatment of COVID-19

Both remdesivir and dexamethasone have been promoted as effective treatments for COVID-19. JAMA Deputy Editor Greg Curfman, MD, and Professor Rachel Sachs, JD, from the Washington University School of Law discuss the science and health policy aspects of these COVID-19 treatments. Related Article(s): Missed Opportunities on Emergency Remdesivir Use

Episode metadata supplied by the publisher feed · Published Jul 20, 2020

Embed this episode

Attribution link and audio player

NOW PLAYING

Remdesivir and Dexamethasone for the Treatment of COVID-19

0:00 36:28

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JAMA Clinical Reviews?

This episode is 36 minutes long.

When was this JAMA Clinical Reviews episode published?

This episode was published on July 20, 2020.

Can I download this JAMA Clinical Reviews episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!